Anupam Rasayan India Ltd has approved a financing structure to support its wholly owned subsidiary, Mates Visa Consultancy Private Limited, through a proposed ₹300 crore secured NCD issue. The company will provide an unconditional corporate guarantee and pledge its entire stake in the subsidiary. It will also pledge its 15% stake in Purebliss Pharma Solutions and enter into a call option agreement. The transaction increases financial flexibility for group entities but also creates contingent liabilities and encumbers equity holdings.
Anupam Rasayan Approves Financing Support for Subsidiary and Associate
**₹300 crore proposed secured NCD issue for subsidiary MVCPL.
100% subsidiary stake to be pledged and unconditional corporate guarantee approved.
Reader Takeaway:** Strong funding support, but higher contingent liabilities and pledged assets deserve monitoring.
What just happened
Anupam Rasayan India Ltd's board has approved the execution of transaction and security documents to facilitate financing for its wholly owned subsidiary, Mates Visa Consultancy Private Limited (MVCPL), and its associate, Purebliss Pharma Solutions Private Limited.
MVCPL proposes to raise up to ₹300 crore through the private placement of up to 30,000 senior secured, unrated, unlisted redeemable non-convertible debentures with a face value of ₹1,00,000 each.
To support this borrowing, Anupam Rasayan will provide an unconditional and irrevocable corporate guarantee in favour of the debenture trustee covering the NCD obligations.
Why this matters
The financing allows the subsidiary to access long-term capital while leveraging the parent's balance sheet and ownership.
For shareholders, the approval creates contingent liabilities because the parent company has guaranteed the debt. It also places security over key investments held by the company.
What changes now
The company will execute a first-ranking pledge over 100% of the equity shares of MVCPL held by it and its nominee shareholder.
Anupam Rasayan will also execute a pledge over its 15% equity stake in Purebliss Pharma Solutions to support financing facilities availed by that associate company.
The board further approved entering into a call option agreement under which the company and its nominee shareholder grant Purebliss an option to acquire all securities of MVCPL held by Anupam Rasayan on a fully diluted basis, subject to the agreed terms.
Risks to watch
Investors should monitor:
- Execution and completion of the financing documents.
- Any invocation of the corporate guarantee.
- The impact of pledged investments on financial flexibility.
- Whether the call option is exercised in the future and how it affects the group's ownership structure.
What to track next
Key developments include the successful placement of the ₹300 crore NCDs, completion of the security documentation, utilisation of the borrowed funds by MVCPL, and any subsequent disclosures relating to the call option arrangement or changes in ownership.